The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro

Breast Cancer

Volumn 24, Issue 5, 2017, Pages 658-666

  Tanaka, Satoshi ^a   Suzuki, Kanayo ^a   Sakaguchi, Minoru ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Cell cycle arrest; Human breast cancer cell lines; Prolyl oligopeptidase; Quiescent G0 state; SUAM 14746

Indexed keywords

3 [(4 (2 STYRYLPHENOXY)BUTANOYL) 4 HYDROXYPROLYL]THIAZOLIDINE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYL THIOPROLYL THIOPROLINAL; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ESTRADIOL; PROLYL ENDOPEPTIDASE; PROLYL ENDOPEPTIDASE INHIBITOR; PROTEIN P130; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; 3-((4-(2-STYRYLPHENOXY)BUTANOYL)-4-HYDROXYPROLYL)THIAZOLIDINE; CCND1 PROTEIN, HUMAN; CCND3 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; E2F1 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROLINE; PROTEINASE INHIBITOR; RB1 PROTEIN, HUMAN; RETINOBLASTOMA BINDING PROTEIN; SERINE PROTEINASE; SMALL INTERFERING RNA; THIAZOLIDINE DERIVATIVE; UBIQUITIN PROTEIN LIGASE;

ARTICLE; BREAST CANCER CELL LINE; CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; EPITHELIAL CELL LINE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; MCF-7 CELL LINE; MCF12A CELL LINE; MDA-MB-231 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; T47D CELL LINE; UPREGULATION; WST-1 ASSAY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECTS; FEMALE; GENE KNOCKDOWN; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; CYCLIN D3; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P27; E2F1 TRANSCRIPTION FACTOR; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE KNOCKDOWN TECHNIQUES; HUMANS; PROLINE; PROTEASE INHIBITORS; RECEPTORS, ESTROGEN; RETINOBLASTOMA BINDING PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES; THIAZOLIDINES; UBIQUITIN-PROTEIN LIGASES;

EID: 85008702266     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-017-0752-5     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71–96.
2. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1–22.
3. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat. 2002;76:27–36.
4. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, et al. Breast cancer. Version 3. J Natl Compr Canc Netw. 2014;12:542–90.
5. Brufsky AM. Delaying chemotherapy in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Med Insights Oncol. 2015;9:137–47.
6. Li Z, Kang Y. Emerging therapeutic targets in metastatic progression: a focus on breast cancer. Pharmacol Ther. 2016;161:79–96.
7. Yoshimoto T, Kado K, Matsubara F, Koriyama N, Kaneto H, Tsuru D. Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect. J Pharmacobiodyn. 1987;10:730–5.
8. Cunningham DF, O’Connor B. Proline specific peptidases. Biochim Biophys Acta. 1997;1343:160–86.
9. Moreno-Baylach MJ, Puttonen KA, Tenorio-Laranga J, Venäläinen JI, Storvik M, Forsberg MM, et al. Prolyl endopeptidase is involved in cellular signaling in human neuroblastoma SH-SY5Y cells. Neurosignals. 2011;19:97–109.
10. Schulz I, Zeitschel U, Rudolph T, Ruiz-Carrillo D, Rahfeld JU, Gerhartz B, et al. Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J Neurochem. 2005;94:970–9.
11. Ishino T, Ohtsuki S, Natori S. cDNA cloning of mouse prolyl endopeptidase and its involvement in DNA synthesis by Swiss 3T3 cells. J Biochem. 1998;123:540–5.
12. Myöhänen TT, Venäläinen JI, Garcia-Horsman JA, Piltonen M, Männisto PT. Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochem Cell Biol. 2008;130:993–1003.
13. Agirregoitia N, Casis L, Gil J, Ruiz F, Irazusta J. Ontogeny of prolyl endopeptidase and pyroglutamyl peptidase I in rat tissues. Regul Pept. 2007;139:52–8.
14. Goossens F, De Meester I, Vanhoof G, Scharpe S. Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur J Clin Chem Clin Biochem. 1996;34:17–22.
15. Larrinaga G, Perez I, Blanco L, López JI, Andrés L, Etxezarraga C, et al. Increased prolyl endopeptidase activity in human neoplasia. Regul Pept. 2010;163:102–6.
16. Sakaguchi M, Matsuda T, Matsumura E, Yoshimoto T, Takaoka M. Prolyl oligopeptidase participates in cell cycle progression in a human neuroblastoma cell line. Biochem Biophys Res Commun. 2011;409:693–8.
17. Suzuki K, Sakaguchi M, Tanaka S, Yoshimoto T, Takaoka M. Prolyl oligopeptidase inhibition-induced growth arrest of human gastric cancer cells. Biochem Biophys Res Commun. 2014;443:91–6.
18. El-Masry OS, Brown BL, Dobson PRM. Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds. Oncol Lett. 2012;3:224–8.
19. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13:215.
20. Schmid I, Cole SW, Korin YD, Zack JA, Giorgi JV. Detection of cell cycle subcompartments by flow cytometric estimation of DNA-RNA content in combination with dual-color immunofluorescence. Cytometry. 2000;39:108–16.
21. Varma H, Skildum AJ, Conrad SE. Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells. PLoS ONE. 2007;2:e1256.
22. 1 phase of the cell cycle. Eur J Cancer Clin Oncol. 1983;19:615–21.
23. Watts CK, Sweeney KJ, Warlters A, Musgrove EA, Sutherland RL. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 1994;31:95–105.
24. Foster JS, Henley DC, Bukovsky A, Seth P, Wimalasena J. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol Cell Biol. 2001;21:794–810.
25. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005;23:4215–24.
26. Yu Q, Sicinska E, Geng Y, Ahnström M, Zagozdzon A, Kong Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006;9:23–32.
27. Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell. 2006;9:13–22.
28. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.
29. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for firstline treatment of ER+/HER2− advanced breast cancer (BC). Cancer Res. 2012;72:S1–6.
30. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427–38.
31. Matsuda T, Sakaguchi M, Tanaka S, Yoshimoto T, Takaoka M. Prolyl oligopeptidase is a glyceraldehyde-3-phosphate dehydrogenase-binding protein that regulates genotoxic stress-induced cell death. Int J Biochem Cell Biol. 2013;45:850–7.